Manulife Announces $5.4 Billion Reinsurance Transaction, Including $2.4 Billion of Long-term Care, With RGA
Manulife Announces $5.4 Billion Reinsurance Transaction, Including $2.4 Billion of Long-term Care, With RGA
Transacting on a younger LTC block further validates LTC reserves and assumptions
Another milestone transaction that optimizes our portfolio
$0.8 billion capital release will be returned to shareholders via share buybacks
Conference call to be held Thursday, November 21, 2024, at 8:00 a.m. ET; details below
在一個較年輕的LTC區塊上進行交易進一步驗證了LTC儲備和假設
另一個里程碑式的交易優化了我們的投資組合
$8億的資本釋放將通過股份回購返還給股東
電話會議將於2024年11月21日星期四上午8:00(東部時間)舉行;詳情如下
TSX/NYSE/PSE: MFC SEHK: 945
C$ unless otherwise stated
TSX/NYSE/PSE: MFC SEHK: 945
除非另有說明,均爲加元
TORONTO, Nov. 20, 2024 /PRNewswire/ - Manulife Financial Corporation ("Manulife" or the "Company") announced today that it has entered into a $5.4 billion1 reinsurance agreement with Reinsurance Group of America ("RGA"), including $2.4 billion of long-term care ("LTC") reserves.
多倫多,2024年11月20日 /PRNewswire/ - 宏利金融公司("宏利"或"公司")今天宣佈已與美國再保險集團("RGA")達成一項54億1的再保險協議,其中包括24億的長期護理("LTC")儲備。
Key highlights of the transaction:
交易的主要亮點:
- Reinsuring $2.4 billion of LTC reserves to RGA on a full risk transfer basis
- Inclusive of our previous LTC reinsurance transaction2 ("previous transaction"), upon closing we will have cumulatively reduced LTC reserves by 18% and LTC morbidity sensitivity by 17%3
- Transacted LTC block is younger, with a greater proportion of active life reserves than our previous transaction
- Modest negative 4% LTC cede4 further validates our reserves and assumptions
- Transaction also includes a legacy block of U.S. structured settlements with $3.0 billion of reserves
- Accretive to core ROE5, and an attractive core earnings5 multiple of 11.4 times6; neutral impact to core EPS5
- Close to 1.0x book value7; expect to release $0.8 billion of capital, which we intend to fully return to shareholders
- Expect to dispose $1.5 billion of alternative long-duration assets ("ALDA")
- 向美國再保險集團再保險24億的長期護理準備金,採用全面風險轉移方式
- 包括我們之前的長期護理再保險交易2("之前的交易"),在完成後我們將累計減少長期護理準備金18%,長期護理發病率敏感性減少17%3
- 交易的長期護理區塊較年輕,活躍壽命準備金的比例大於我們之前的交易
- 適度負面4%的長期護理再保額進一步驗證了我們的準備金和假設
- 交易還包括一筆遺留的美國結構性和解,準備金爲30億
- 對核心roe5產生增值,核心收益5的倍數吸引,爲11.4倍6;對核心每股收益5影響中立
- 接近1.0倍的賬面價值7;預計釋放8億的資本,我們打算將其全部返還給股東
- 預計處置15億的另類長期資產("ALDA")
"We are further unlocking significant shareholder value with a second milestone LTC reinsurance transaction within 12 months, which accelerates our transformation to reshape our portfolio towards higher return and lower risk. This transaction further demonstrates our ability to execute on complex transactions and collaborate with experienced counterparties to deliver win-win outcomes, including on both mature and younger LTC blocks. The deal is priced at 11.4 times core earnings multiple and is expected to be accretive to core ROE after we return the released capital to shareholders through share buybacks." — Roy Gori, Manulife President & Chief Executive Officer "Together with our previously completed LTC transaction, we will have cumulatively reduced our LTC reserves by 18% within a year, upon closing, meaningfully improving the return profile of our inforce business. The pricing of this transaction further validates our prudent LTC reserves and assumptions. There continues to be attractive opportunities to generate shareholder value through organic LTC optimization, and we remain open to further inorganic opportunities." — Marc Costantini, Manulife Global Head of Strategy and Inforce Management |
「在12個月內,我們正進一步解鎖顯著的股東價值,進行第二個里程碑的長期護理再保險交易,這加快了我們的轉型,旨在重新塑造我們的投資組合,實現更高的回報和更低的風險。這筆交易進一步展示了我們執行復雜交易的能力,以及與經驗豐富的對手方合作以實現雙贏結果的能力,包括在成熟和年輕的長期護理業務區塊上。該交易的定價爲核心收益的11.4倍,並預計在我們通過股票回購將釋放的資本返還給股東後,對核心roe產生收益。」 —— 宏利金融總裁兼首席執行官 羅伊·戈裏 「加上我們之前完成的長期護理交易,我們將在交易完成後的1年內累計減少18%的長期護理準備金,顯著改善我們現有業務的回報狀況。此交易的定價進一步驗證了我們謹慎的長期護理準備金和假設。通過有機的長期護理優化,繼續存在吸引股東價值的機會,我們仍然開放於進一步的非有機機會。」 —— 馬克·科斯坦蒂尼, 宏利金融全球戰略與現有業務管理負責人 |
Transaction Summary
交易摘要
We will reinsure a combined $5.4 billion of reserves across two blocks of legacy business to RGA. The blocks include portions of U.S. LTC and U.S. structured settlements. The LTC block represents $2.4 billion, or 6% of Manulife's total LTC reserves as of September 30, 2024. The transaction is priced at close to 1.0 times book value, reflecting a modest negative ceding commission on LTC, and a nominal ceding commission on the structured settlements block.
我們將通過再保險將54億加幣的準備金分配給美國再保險集團。該業務塊包括美國長期護理(LTC)和美國結構性和解的部分。長期護理業務塊佔Manulife截至2024年9月30日總長期護理準備金的24億加幣,即6%。該交易的定價接近於賬面價值的1.0倍,反映了長期護理的適度負轉付佣金和針對結構性和解業務塊的名義轉付佣金。
RGA is a highly experienced global reinsurer with multiple existing reinsurance arrangements with Manulife. The transaction includes significant structural protections, including over-collateralized trusts to hold investment assets. The reinsurance represents a 75% quota share on both ceded blocks.
美國再保險集團是一家經驗豐富的全球再保險公司,與Manulife已有多項現有再保險安排。該交易包含顯著的結構保護,包括超額擔保信託以持有投資資產。再保險代表兩個轉讓塊的75%配額分享。
In connection with the transaction, we expect to dispose $1.5 billion of ALDA. Manulife will continue to administer all reinsured policies for a seamless customer service experience. The transaction is expected to close in early 2025, subject to customary closing conditions.
與該交易相關,我們預計將處置15億加幣的ALDA。Manulife將繼續管理所有再保險的保單,以提供無縫的客戶服務體驗。該交易預計將在2025年初完成,需遵循慣例的閉合條件。
Transacting on a younger LTC block further validates LTC reserves and assumptions
在一個較年輕的LTC區塊上進行交易進一步驗證了LTC儲備和假設
The transaction will reduce LTC reserves by $2.4 billion, or 6%, and is expected to reduce the underlying LTC reserve sensitivity to changes in morbidity assumptions by 7%. The transaction represents a full risk transfer on a younger LTC block, which has similar characteristics to our retained LTC blocks, with a greater proportion of active life reserves than the ceded block in our previous LTC reinsurance transaction.
該交易將減少24億加幣的長期護理準備金,或6%,預計將使基礎長期護理準備金對發病假設變化的敏感性降低7%。該交易代表對一個年輕的長期護理塊的全面風險轉移,該塊的特徵與我們保留的長期護理塊類似,活躍生活準備金的比例大於我們之前的長期護理再保險交易中的轉讓塊。
Including our previous LTC reinsurance transaction, which closed in February 2024, we will have cumulatively reduced LTC reserves and morbidity sensitivity by 18% and 17%, respectively, upon closing. This demonstrates our proven ability to transact on both mature and younger LTC blocks.
包括我們在2024年2月完成的之前的長期護理再保險交易,我們通常將在交易完成時累計將長期護理準備金和發病敏感性分別降低18%和17%。這證明了我們在成熟和年輕的長期護理塊上進行交易的能力。
The modest negative ceding commission on the LTC block of 4% of IFRS reserves further validates our LTC reserves and assumptions.
長期護理塊4%的適度負轉付佣金進一步驗證了我們的長期護理準備金和假設。
Unlocks Value for Shareholders
爲股東解鎖價值
The transaction is expected to release $0.8 billion of capital, which we intend to fully return to shareholders through common share buybacks post-closing. We are committed to repurchasing for cancellation the full 90 million common shares allowed under our current NCIB program, which expires in February 2025. Further buybacks beyond the 90 million shares common shares allowed under our current NCIB program will require a new NCIB program, which will be subject to the approval of the Office of the Superintendent of Financial Institutions ("OSFI") and the Toronto Stock Exchange ("TSX").
此次交易預計將釋放8億資本,我們意圖在交易完成後通過回購普通股完全返還給股東。我們承諾根據目前的NCIb計劃回購9000萬普通股以供註銷,該計劃將於2025年2月到期。在當前NCIb計劃允許的9000萬普通股之外的進一步回購將需要新的NCIb計劃,該計劃將需經金融機構監管辦公室("OSFI")及多倫多證券交易所("tsx")批准。
The transaction is priced at close to 1.0 times book value and is expected to result in an annual reduction to core earnings and net income attributed to shareholders of $70 million and $50 million, respectively. With a capital release of $0.8 billion, the transaction represents a deal multiple of 11.4 times core earnings. The transaction is expected to be accretive to core ROE, and have a neutral impact on core EPS, after the impact of expected share buybacks.
此次交易的定價接近於賬面價值1.0倍,預計將導致股東核心收益和淨利潤分別減少7000萬和5000萬。隨着8億資本的釋放,此次交易代表一個11.4倍的核心收益倍數。預計該交易將對核心ROE產生增益,並對核心每股收益產生中立影響,考慮到預計的股票回購影響。
Conference Call
電話會議
A live webcast and conference call are scheduled for Thursday, November 21, 2024, at 8:00 a.m. (ET), where Roy Gori, President and CEO, Marc Costantini, Global Head of Strategy and Inforce Management, and other members of Manulife's executive leadership team will discuss the transaction, followed by a question and answer period with analysts.
定於2024年11月21日星期四上午8:00(東部時間)進行現場網絡廣播和電話會議,屆時宏利的總裁兼首席執行官Roy Gori、全球戰略及在役管理負責人Marc Costantini及其他宏利執行領導團隊成員將討論此次交易,隨後與分析師進行問答環節。
To access the conference call, dial 1-800-806-5484 or 1-416-340-2217 (Passcode: 1915608#). Please call in 15 minutes before the scheduled start time.
要訪問電話會議,請撥打1-800-806-5484或1-416-340-2217(密碼:1915608#)。請在預定開始時間前15分鐘撥入。
Slides related to this announcement are available on the Manulife website.
與此公告相關的幻燈片可在宏利網站上獲取。
About Manulife
關於宏利
Manulife Financial Corporation is a leading international financial services provider, helping people make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we provide financial advice and insurance, operating as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2023, we had more than 38,000 employees, over 98,000 agents, and thousands of distribution partners, serving over 35 million customers. We trade as 'MFC' on the Toronto, New York, and the Philippine stock exchanges, and under '945' in Hong Kong.
宏利金融集團是全球領先的國際金融服務提供商,幫助人們更輕鬆地做出決策,使生活更美好。總部設在加拿大多倫多,我們在加拿大、亞洲和歐洲以宏利的名義提供金融諮詢和保險業務,在美國主要以約翰漢考克的名義運營。通過宏利財富與資產管理,我們爲全球個人、機構和退休計劃會員提供全球投資、金融諮詢和養老計劃服務。截至2023年底,我們擁有超過38,000名員工、超過98,000名代理人和數千名分銷合作伙伴,爲超過3500萬客戶提供服務。我們在多倫多、紐約和菲律賓股票交易所上市爲'MFC',在香港則以'945'交易。
Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com.
並非所有產品在所有司法管轄區均可提供。如需更多信息,請訪問manulife.com。
About RGA
關於RGA
Reinsurance Group of America, Incorporated (NYSE: RGA) is a global industry leader specializing in life and health reinsurance and financial solutions that help clients effectively manage risk and optimize capital. Founded in 1973, RGA is today one of the world's largest and most respected reinsurers and remains guided by a powerful purpose: to make financial protection accessible to all. As a global capabilities and solutions leader, RGA empowers partners through bold innovation, relentless execution, and dedicated client focus — all directed toward creating sustainable long-term value. RGA has approximately US$4.0 trillion of life reinsurance in force and assets of US$120.3 billion as of September 30, 2024. To learn more about RGA and its businesses, please visit rgare.com or follow RGA on LinkedIn and Facebook. Investors can learn more at investor.rgare.com.
Reinsurance Group of America, Incorporated (NYSE: RGA) is a global industry leader specializing in life and health reinsurance and financial solutions that help clients effectively manage risk and optimize capital. Founded in 1973, RGA is today one of the world's largest and most respected reinsurers and remains guided by a powerful purpose: to make financial protection accessible to all. As a global capabilities and solutions leader, RGA empowers partners through bold innovation, relentless execution, and dedicated client focus — all directed toward creating sustainable long-term value. RGA has approximately US$4萬億 of life reinsurance in force and assets of US$1203億 as of September 30, 2024. To learn more about RGA and its businesses, please visit rgare.com or follow RGA on LinkedIn and Facebook. Investors can learn more at investor.rgare.com.
_________ | |
Note: All figures and estimates are based on September 30, 2024, position, unless otherwise noted, and are expressed in Canadian dollar, based on exchange rate of US$1:00 to C$1.351 | |
1 |
IFRS 17 current estimate of present value of future cash flows + risk adjustment + contractual service margin. |
2 |
Refers to the $13 billion reinsurance transaction, including $6 billion of LTC, with Global Atlantic that was announced in December 2023 and closed in February 2024. |
3 |
Impact of a change in reserves would be reported through the contractual service margin, net income attributed to shareholders, and other comprehensive income attributed to shareholders. Morbidity sensitivity is based on 2Q24, grossed up for 3Q24 reserves. Transaction is expected to close in early 2025 and is subject to customary closing conditions. |
4 |
On IFRS basis. |
5 |
Core return on shareholders' equity ("Core ROE") and diluted core earnings per common share ("Core EPS") are non-GAAP ratios. Core earnings is a non-GAAP financial measure. See "Non-GAAP and other financial measures" below and in our 3Q24 Management Discussion and Analysis ("3Q24 MD&A"). |
6 |
On IFRS basis. Ratio of the capital release to annual core earnings impact. |
7 |
On IFRS basis. Ratio of the market value of assets transferred to the sum of IFRS 17 current estimate of present value of future cashflows + risk adjustment + contractual service margin. |
_________ | |
Note: All figures and estimates are based on September 30, 2024, position, unless otherwise noted, and are expressed in Canadian dollar, based on exchange rate of US$1:00 to C$1.351 | |
1 |
國際財務報告準則17當前未來現金流現值的估計 + 風險調整 + 合同服務邊際。 |
2 |
指的是130億的再保險交易,包括60億的長期護理保險,與全球貨幣的Global Atlantic於2023年12月宣佈,並於2024年2月完成。 |
3 |
儲備變化的影響將通過合同服務邊際、歸屬於股東的淨利潤以及歸屬於股東的其他綜合收益予以報告。發病率敏感性基於2024年第二季度,並根據2024年第三季度的儲備進行調整。交易預計將在2025年初完成,並需遵循慣例的關閉控件。 |
4 |
在國際財務報告準則基礎上。 |
5 |
核心股東權益回報率("核心roe")和每股稀釋核心收益("核心每股收益")是非公認會計原則(非GAAP)比率。核心收益是一個非GAAP財務指標。請參閱下面的"非GAAP及其他財務指標"以及我們3Q24管理討論與分析("3Q24 MD&A")。 |
6 |
按國際財務報告準則計算。資本釋放與年度核心收益影響的比率。 |
7 |
按 IFRS 基礎。轉移資產的市場價值與 IFRS 17 當前估計的未來現金流現值之和 + 風險調整 + 合同服務邊際的比率。 |
Non-GAAP and other financial measures
非 GAAP 和其他財務措施
Manulife prepares its Consolidated Financial Statements in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board. We use a number of non-GAAP and other financial measures to evaluate overall performance and to assess each of our businesses. This section includes information required by National Instrument 52-112 – Non-GAAP and Other Financial Measures Disclosure in respect of "specified financial measures" (as defined therein). Core earnings is a Non-GAAP financial measure and diluted core earnings per common share and core ROE are Non-GAAP ratios. For more information on the non-GAAP financial measures and non-GAAP ratios in this document please see section E3 "Non-GAAP and other financial measures" of the 3Q24 MD&A which is incorporated by reference and available on the SEDAR+ website at .
宏利按照國際會計準則委員會發布的國際財務報告準則("IFRS")編制其合併財務報表。我們使用多種非 GAAP 和其他財務措施來評估整體業績並評估每個業務。本節包括根據國家工具 52-112 - 非 GAAP 和其他財務措施披露所需的信息,涉及「指定財務措施」(按其中定義)。核心收益是非 GAAP 財務措施,稀釋後每股核心收益和核心淨資產收益率是非 GAAP 比率。有關本文件中非 GAAP 財務措施和非 GAAP 比率的更多信息,請參見 3Q24 MD&A 的 E3 節 "非 GAAP 和其他財務措施",該文檔已通過引用並可在 SEDAR+ 網站上獲取。
CAUTION REGARDING FORWARD-LOOKING STATEMENTS:
關於前瞻性聲明的警告:
From time to time, Manulife makes written and/or oral forward-looking statements, including in this document. In addition, our representatives may make forward-looking statements orally to analysts, investors, the media and others. All such statements are made pursuant to the "safe harbour" provisions of Canadian provincial securities laws and the U.S. Private Securities Litigation Reform Act of 1995.
宏利不時做出書面和/或口頭的前瞻性聲明,包括在本文件中。此外,我們的代表可能會口頭向分析師、投資者、媒體和其他人做出前瞻性聲明。所有此類聲明均根據加拿大省證券法和美國1995年私人證券訴訟改革法的「安全港」條款作出。
The forward-looking statements in this document include, but are not limited to, statements with respect to the disposal of ALDA assets, the expected closing time of the reinsurance transaction referred to in this document and its associated capital release, possible share buybacks, and organic LTC optimization and also relate to, among other things, our objectives, goals, strategies, intentions, plans, beliefs, expectations and estimates, and can generally be identified by the use of words such as "may", "will", "could", "should", "would", "likely", "suspect", "outlook", "expect", "intend", "estimate", "anticipate", "believe", "plan", "forecast", "objective", "seek", "aim", "continue", "goal", "restore", "embark" and "endeavour" (or the negative thereof) and words and expressions of similar import, and include statements concerning possible or assumed future results. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements and they should not be interpreted as confirming market or analysts' expectations in any way.
本文件中的前瞻性陳述包括但不限於關於處理ALDA資產、本文中提到的再保險交易的預期完成時間及其相關資本釋放、可能的股份回購、以及有機LTC優化的聲明,還涉及我們的目標、戰略、意圖、計劃、信念、期望和估計,通常可以通過使用諸如「可能」、「將」、「能夠」、「應該」、「會」、「可能」、「懷疑」、「展望」、「期望」、「打算」、「估計」、「預期」、「相信」、「計劃」、「預測」、「目標」、「尋求」、「目的」、「繼續」、「目標」、「恢復」、「開始」和「努力」(或其否定形式)以及具有類似含義的詞語和表達來識別,幷包括關於可能或假設的未來結果的聲明。儘管我們相信這些前瞻性陳述中反映的期望是合理的,但這些陳述涉及風險和不確定性,不應過度依賴這些陳述,並且不應被解讀爲以任何方式確認市場或分析師的期望。
Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from expectations include but are not limited to: general business and economic conditions (including but not limited to the performance, volatility and correlation of equity markets, interest rates, credit and swap spreads, inflation rates, currency rates, investment losses and defaults, market liquidity and creditworthiness of guarantors, reinsurers and counterparties); the satisfaction of customary closing conditions in connection with the reinsurance transaction described herein; the ongoing prevalence of COVID-19, including any variants, as well as actions that have been, or may be taken by governmental authorities in response to COVID-19, including the impact of any variants; changes in laws and regulations; changes in accounting standards applicable in any of the territories in which we operate; changes in regulatory capital requirements; our ability to obtain premium rate increases on in-force policies; our ability to execute strategic plans and changes to strategic plans; downgrades in our financial strength or credit ratings; our ability to maintain our reputation; impairments of goodwill or intangible assets or the establishment of provisions against future tax assets; the amount of contractual service margin recognized for service provided; the accuracy of estimates relating to morbidity, mortality and policyholder behaviour; the accuracy of other estimates used in applying accounting policies, actuarial methods and embedded value methods; our ability to implement effective hedging strategies and unforeseen consequences arising from such strategies; our ability to source appropriate assets to back our long-dated liabilities; level of competition and consolidation; our ability to market and distribute products through current and future distribution channels; unforeseen liabilities or asset impairments arising from acquisitions and dispositions of businesses; the realization of losses arising from the sale of investments classified as fair value through other comprehensive income; our liquidity, including the availability of financing to satisfy existing financial liabilities on expected maturity dates when required; obligations to pledge additional collateral; the availability of letters of credit to provide capital management flexibility; accuracy of information received from counterparties and the ability of counterparties to meet their obligations; the availability, affordability and adequacy of reinsurance; legal and regulatory proceedings, including tax audits, tax litigation or similar proceedings; our ability to adapt products and services to the changing market; our ability to attract and retain key executives, employees and agents; the appropriate use and interpretation of complex models or deficiencies in models used; political, legal, operational and other risks associated with our non-North American operations; geopolitical uncertainty, including international conflicts, acquisitions or divestitures, and our ability to complete transactions; environmental concerns, including climate change; our ability to protect our intellectual property and exposure to claims of infringement; and our inability to withdraw cash from subsidiaries and the fact that the amount and timing of any future common share repurchases will depend on the earnings, cash requirements and financial condition of Manulife, market conditions, capital requirements (including under LICAT capital standards), common share issuance requirements, applicable law and regulations (including Canadian and U.S. securities laws and Canadian insurance company regulations), and other factors deemed relevant by Manulife, and may be subject to regulatory approval or conditions, our ability to sell ALDA assets and our ability to execute our plans for inorganic LTC initiatives and close the reinsurance transaction described in this document.
在做出前瞻性陳述時應用了某些實質性因素或假設,實際結果可能與這些陳述中表達或暗示的結果有顯著差異。可能導致實際結果與期望顯著不同的重要因素包括但不限於:一般商業和經濟條件(包括但不限於股市的表現、波動性和相關性,利率,信用和互換利差,通貨膨脹率,貨幣匯率,投資損失和違約,市場流動性以及擔保人、再保險人和交易對手的信用worthiness);與本文所述再保險交易相關的常見交易條件的滿足;COVID-19持續流行,包括任何變種,以及政府當局可能採取的應對COVID-19的舉措,包括對任何變種的影響;法律和法規的變化;適用於我們運營的任何地區的會計標準變更;監管資本要求的變化;我們獲得在保單上的保費率上漲的能力;我們執行戰略計劃和對戰略計劃的更改的能力;我們的金融實力或信用評級的降級;我們維護聲譽的能力;商譽或無形資產的減值或未來稅收資產的減值準備的建立;爲所提供服務確認的合同服務邊際的金額;與發病率、死亡率和保單持有人行爲相關的估計的準確性;在應用會計政策、精算方法和嵌入價值方法時所使用的其他估計的準確性;我們實施有效對沖策略的能力和由此產生的意外結果;我們爲長期負債尋找適當資產的能力;競爭和整合的水平;我們通過當前和未來的分銷渠道營銷和分銷產品的能力;因企業收購和處置而產生的意外負債或資產減值;出售被分類爲其他綜合收益的投資所產生的損失的實現;我們的流動性,包括在需要時滿足現有財務負債的預期到期日的融資可用性;追加擔保的義務;提供資本管理靈活性的信用證的可用性;從交易對手收到的信息的準確性及交易對手履行其義務的能力;再保險的可用性、可負擔性和充分性;法律和監管程序,包括稅務審計、稅務訴訟或類似程序;我們適應市場變化的產品和服務的能力;我們吸引和留住關鍵高管、員工和代理人的能力;複雜模型的適當使用和解釋或使用模型時的缺陷;與我們的非北美業務相關的政治、法律、運營和其他風險;地緣政治不確定性,包括國際衝突、收購或剝離,以及我們完成交易的能力;環境問題,包括氣候變化;我們保護知識產權的能力及面臨侵權索賠的風險;我們無法從子公司提取現金,以及未來回購普通股的數量和時間將取決於宏利的收益、現金需求和財務狀況、市場條件、資本需求(包括根據LICAt資本標準)、普通股發行要求、適用法律和法規(包括加拿大和美國證券法及加拿大保險公司法規)以及宏利認爲相關的其他因素,並可能受到監管批准或條件的限制,我們出售ALDA資產的能力,以及我們執行無機LTC計劃和完成本文中所述的再保險交易的能力。
Additional information about material risk factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in our 3Q24 Management's Discussion and Analysis under "Risk Management and Risk Factors Update" and "Critical Actuarial and Accounting Policies", in our 2023 Management's Discussion and Analysis under "Risk Management and Risk Factors" and "Critical Actuarial and Accounting Policies", and in the "Risk Management" note to the Consolidated Financial Statements in our most recent annual and interim reports and elsewhere in our filings with Canadian and U.S. securities regulators.
關於可能導致實際結果與預期存在重大差異的重大風險因素的附加信息,以及在做出前瞻性聲明時所使用的重大因素或假設,可以在我們2024年第三季度的管理討論與分析中找到,涉及「風險管理和風險因素更新」以及「關鍵精算和會計政策」,在我們2023年的管理討論與分析中也有提到這些內容,涉及「風險管理和風險因素」以及「關鍵精算和會計政策」,此外,還可以在我們最新的年度和中期報告及其他向加拿大和美國證券監管機構提交的文件中的「風險管理」附註中找到。
The forward-looking statements in this document are, unless otherwise indicated, stated as of the date hereof and are presented for the purpose of assisting investors and others in understanding our financial position and results of operations, our future operations, as well as our objectives and strategic priorities, and may not be appropriate for other purposes. We do not undertake to update any forward-looking statements, except as required by law.
本文件中的前瞻性聲明,除非另有說明,均爲截至本日期的表述,目的是爲了幫助投資者和其他相關方理解我們的財務狀況和運營結果、未來運營,以及我們的目標和戰略優先事項,可能不適用於其他目的。除法律要求外,我們不承擔更新任何前瞻性聲明的義務。
SOURCE Manulife Financial Corporation
SOURCE宏利金融公司